TriSalus Life Sciences, Inc.
TLSI
$5.10
$0.173.45%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 45.50% | 46.21% | 59.00% | 67.91% | 67.75% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 45.50% | 46.21% | 59.00% | 67.91% | 67.75% |
| Cost of Revenue | 80.65% | 58.79% | 57.50% | 22.19% | 3.49% |
| Gross Profit | 40.55% | 44.29% | 59.25% | 77.76% | 83.83% |
| SG&A Expenses | 11.23% | 8.50% | 20.94% | 29.40% | 42.79% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.44% | -13.16% | -4.42% | 6.88% | 30.19% |
| Operating Income | 36.00% | 38.41% | 27.84% | 13.65% | -16.83% |
| Income Before Tax | 42.90% | 57.64% | 49.34% | -20.29% | -3.27% |
| Income Tax Expenses | -118.18% | -52.94% | -33.33% | -42.86% | -21.43% |
| Earnings from Continuing Operations | 42.91% | 57.64% | 49.34% | -20.27% | -3.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 42.91% | 57.64% | 49.34% | -20.27% | -3.26% |
| EBIT | 36.00% | 38.41% | 27.84% | 13.65% | -16.83% |
| EBITDA | 36.51% | 39.03% | 28.32% | 14.12% | -16.79% |
| EPS Basic | 53.37% | 97.07% | 96.51% | 97.75% | 98.16% |
| Normalized Basic EPS | 68.50% | 95.48% | 95.34% | 97.64% | 97.17% |
| EPS Diluted | 53.37% | 97.07% | 96.51% | 97.75% | 98.16% |
| Normalized Diluted EPS | 68.50% | 95.48% | 95.34% | 97.64% | 97.17% |
| Average Basic Shares Outstanding | 38.08% | 76.96% | 91.03% | 221.86% | 384.45% |
| Average Diluted Shares Outstanding | 38.08% | 76.96% | 91.03% | 221.86% | 384.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |